Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
Language English Country England, Great Britain Media print-electronic
Document type Clinical Trial, Journal Article, Multicenter Study, Observational Study
Grant support
PROGRES Q26/LF1
Ministry of Education, Youth, and Sports
PROGRES Q28/LF1
Ministry of Education, Youth, and Sports
NPU I nr. LO1604
Ministry of Education, Youth, and Sports
AZV 17-28980A (All rights reserved)
Ministry of Health of the Czech Republic
00064203
University Hospital Motol
CZ.2.16/3.1.00/24505
EU-Prague
GAUK 20214
Grant Agency of Charles University
UNCE/MED/016
Charles University Center of Excellence
PubMed
30129045
DOI
10.1002/hon.2550
Knihovny.cz E-resources
- Keywords
- PET-CT, elderly patients, maintenance rituximab, mantle cell lymphoma, minimal residual disease,
- MeSH
- Cyclophosphamide administration & dosage MeSH
- Doxorubicin administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma, Mantle-Cell * blood drug therapy mortality MeSH
- Survival Rate MeSH
- Antibodies, Monoclonal, Murine-Derived administration & dosage MeSH
- Follow-Up Studies MeSH
- Prednisone administration & dosage MeSH
- Disease-Free Survival MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Neoplasm, Residual MeSH
- Rituximab administration & dosage MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Maintenance Chemotherapy * MeSH
- Vincristine administration & dosage MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Names of Substances
- Cyclophosphamide MeSH
- Doxorubicin MeSH
- Antibodies, Monoclonal, Murine-Derived MeSH
- Prednisone MeSH
- R-CHOP protocol MeSH Browser
- Rituximab MeSH
- Vincristine MeSH
Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
1st Medical Department Charles University General Hospital Prague Czech Republic
Department of Hematology and Oncology Masaryk University Hospital in Brno Czech Republic
References provided by Crossref.org
Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
